BioWorld

Nov. 19, 2003

View Archived Issues

Neose, Novo Enter Potential $55.6M Protein License Dea

Diabetic Mice Reveal Insulin In Spleen Cells, Pointing To Human Type I Cure In Pending Clinicals

Focused On Brain, CNS Disorders, Saegis Raises $30M In Its Series B

Phoenix Pharmacologics Starts Phase III Study In Liver Cancer

Keryx Has Cash For Three Years After $15M Private Placement

Vitex Halts Phase III Chronic Trial Of Inactine, Seeks New Financing

Other News To Note

Genome Therapeutics, Genesoft To Merge In $80M All-Stock Deal

Genome Therapeutics Inc. and Genesoft Pharmaceuticals Inc. said they have entered a definitive agreement for an all-stock merger that would leave the new entity with one antibiotic preparing to launch and another in Phase III trials. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...